Modified Hoehn and Yahr Scale for Parkinson's Disease
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Stage 11–1
- Stage 1.51.5–1.5
- Stage 22–2
- Stage 2.52.5–2.5
The Modified Hoehn and Yahr Scale for Parkinson's Disease calculates quantifying neurological deficit severity, stroke volume, and reperfusion therapy eligibility. Key inputs include clinical stage. Scores guide initiating intravenous thrombolysis, activating endovascular thrombectomy pathways, or secondary prevention protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Grades severity of symptoms in Parkinson's disease with intermediate stages for better disease progression tracking
Clinical Indication
The Modified Hoehn and Yahr Scale for Parkinson's Disease is indicated for bedside clinical practice to support Grades severity of symptoms in Parkinson's disease with intermediate stages for better disease progression tracking. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute neurological deficits, acute ischemic stroke, intracranial hemorrhage, seizures, or altered mental status. Clinical application is indicated across Comprehensive stroke centers, acute neurovascular units, neuro-ICU, and emergency neurology services.
Limitations & Contraindications
Stroke mimics including severe hypoglycemia, Todd postictal paresis, and hemiplegic migraine must be ruled out prior to intravenous thrombolysis.
Clinical Pearls & Action Plan
Time is brain; rapid determination of Last Known Well time and baseline functional status dictates reperfusion eligibility. Guideline pearl: Movement Disorder Society recommends using original 1-5 scale due to lack of validation of 0.5 increments.
Clinical staging based on motor symptoms: Stage 1 (unilateral), 1.5 (unilateral + axial), 2 (bilateral, balance intact), 2.5 (bilateral, recovers on pull-test), 3 (bilateral, postural instability), 4 (severe disability, independent), 5 (wheelchair/bed-bound).
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| clinical_stage | string | Yes | Clinical stage based on motor symptoms and functional disability |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Stage 1 | Unilateral involvement only |
| 1.5–1.5 | Stage 1.5 | Unilateral and axial involvement |
| 2–2 | Stage 2 | Bilateral involvement without impairment of balance |
| 2.5–2.5 | Stage 2.5 | Mild bilateral disease with recovery on pull test |
| 3–3 | Stage 3 | Bilateral disease; mild to moderate disability |
| 4–4 | Stage 4 | Severe disability; still able to walk or stand unassisted |
| 5–5 | Stage 5 | Confinement to bed or wheelchair unless aided |
Evidence-Based References (EBM)
- Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427-42. doi: 10.1212/wnl.17.5.427.DOI: 10.1212/wnl.17.5.427
- Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L; Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. Mov Disord. 2004 Sep;19(9):1020-8. doi: 10.1002/mds.20213.DOI: 10.1002/mds.20213
- Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol. 2010 Jan;67(1):64-70. doi: 10.1001/archneurol.2009.295.DOI: 10.1001/archneurol.2009.295